Clinical Trial Update: Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor. [Phase 1, Phase 2]

View source ↗

Summary

A study evaluating ribociclib in combination with everolimus and exemestane in HR-positive, HER2-negative locally advanced or metastatic breast cancer after pro…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Everolimus (everolimus)
• Exemestane (Exemestane)
• Ribociclib (ribociclib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-05-05